title: Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations.
abstract: OBJECTIVE
  Chemotherapy-induced peripheral neuropathy (CIPN) is increasing with introduction of new and combination cancer pharmacotherapies. This study evaluated associations between clinical and self-report measurements and current perception threshold (CPT), a neuroselective measure of sensory nerve function that may detect asymptomatic CIPN damage.
  
  
  METHODS
  Data for this secondary analysis were from a prospective, observational study using CPT to evaluate CIPN. Bivariate mixed models, accounting for the intraclass correlation between repeated patient assessments, were used to assess the relationship between CPT at each frequency (5, 250, and 2,000 Hz) and each subjective measure (Neuropathic Pain Scale, FACT-GOGntx) and objective measurement (quantitative sensory testing, deep tendon reflexes, and grip strength).
  
  
  RESULTS
  A total of 29 chemotherapy-naïve subjects with various cancer types had a mean age of 56.7 (SD 10.4); nine subjects developed CIPN grade >1 using NCI CTC-AE criteria. Cold detection thresholds were inversely associated with CPT 5 [b(95 % CI) = -2.5(-4.5, -0.5)] and CPT 2,000 [-7.5(-11.8, -3.3)] frequencies. FACT GOG-ntx quality of life (QoL) scale and neurotoxicity and function subscales were inversely associated with CPT 2,000 [-1.8 (-3.5, -0.05), -2.2 (-4.2, -0.2), and -5.4 (-9.8, -0.9), respectively], indicating worsening QoL, impairment, and function as hypoesthesia increases.
  
  
  CONCLUSIONS
  CPT 2,000 may identify impending worsening of patient-reported outcomes such as QoL.
authors.affiliation: University of Maryland School of Nursing, Lombard Street, Baltimore, MD, 21201, USA, Griffith@son.umaryland.edu.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Griffith
authors.forename: Darren J
authors.initials: DJ
authors.lastname: Couture
authors.forename: Shijun
authors.initials: S
authors.lastname: Zhu
authors.forename: Naimish
authors.initials: N
authors.lastname: Pandya
authors.forename: Mary E
authors.initials: ME
authors.lastname: Johantgen
authors.forename: Guido
authors.initials: G
authors.lastname: Cavaletti
authors.forename: Joan M
authors.initials: JM
authors.lastname: Davenport
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Tanguay
authors.forename: Amanda
authors.initials: A
authors.lastname: Choflet
authors.forename: Todd
authors.initials: T
authors.lastname: Milliron
authors.forename: Erica
authors.initials: E
authors.lastname: Glass
authors.forename: Nancy
authors.initials: N
authors.lastname: Gambill
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Renn
authors.forename: Susan G
authors.initials: SG
authors.lastname: Dorsey
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D020258:Neurotoxicity Syndromes / Q000175:diagnosis*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D011446:Prospective Studies; D011788:Quality of Life; D057566:Self Report; D012684:Sensory Thresholds / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents